NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,084 | -38.2% | 5,177 | -40.4% | 0.00% | – |
| Q2 2023 | $4,993 | -89.6% | 8,680 | -87.3% | 0.00% | – |
| Q1 2023 | $48,033 | +55.7% | 68,336 | +400.6% | 0.00% | – |
| Q4 2022 | $30,853 | -55.9% | 13,652 | -37.7% | 0.00% | – |
| Q3 2022 | $70,000 | -16.7% | 21,919 | -1.1% | 0.00% | – |
| Q2 2022 | $84,000 | -85.8% | 22,158 | -79.7% | 0.00% | – |
| Q1 2022 | $590,000 | -62.0% | 109,363 | -4.8% | 0.00% | – |
| Q4 2021 | $1,553,000 | -46.9% | 114,910 | -29.4% | 0.00% | -100.0% |
| Q3 2021 | $2,922,000 | -7.4% | 162,697 | -11.5% | 0.00% | 0.0% |
| Q2 2021 | $3,155,000 | -17.7% | 183,811 | -4.0% | 0.00% | 0.0% |
| Q1 2021 | $3,832,000 | -11.1% | 191,548 | -24.4% | 0.00% | 0.0% |
| Q4 2020 | $4,310,000 | +50.6% | 253,515 | +47.0% | 0.00% | 0.0% |
| Q3 2020 | $2,861,000 | -52.9% | 172,504 | -34.3% | 0.00% | -50.0% |
| Q2 2020 | $6,077,000 | +27.2% | 262,392 | -2.0% | 0.00% | 0.0% |
| Q1 2020 | $4,777,000 | -14.7% | 267,623 | +3.2% | 0.00% | 0.0% |
| Q4 2019 | $5,597,000 | -21.5% | 259,337 | -33.7% | 0.00% | 0.0% |
| Q3 2019 | $7,128,000 | -40.8% | 391,335 | +15.6% | 0.00% | -33.3% |
| Q2 2019 | $12,047,000 | -22.3% | 338,614 | -26.6% | 0.00% | -40.0% |
| Q1 2019 | $15,504,000 | +42.8% | 461,412 | +39.7% | 0.01% | +25.0% |
| Q4 2018 | $10,859,000 | -57.0% | 330,356 | -20.2% | 0.00% | -42.9% |
| Q3 2018 | $25,246,000 | +186.7% | 414,142 | +129.7% | 0.01% | +133.3% |
| Q2 2018 | $8,805,000 | -61.9% | 180,323 | -17.1% | 0.00% | -57.1% |
| Q1 2018 | $23,113,000 | +141.1% | 217,518 | +35.5% | 0.01% | +133.3% |
| Q4 2017 | $9,587,000 | +85.3% | 160,523 | -25.5% | 0.00% | +50.0% |
| Q3 2017 | $5,174,000 | +28.9% | 215,561 | +5.0% | 0.00% | +100.0% |
| Q2 2017 | $4,015,000 | -17.5% | 205,372 | -0.9% | 0.00% | -50.0% |
| Q1 2017 | $4,866,000 | +105.4% | 207,320 | +7.4% | 0.00% | +100.0% |
| Q4 2016 | $2,369,000 | +19.6% | 193,118 | +67.5% | 0.00% | 0.0% |
| Q3 2016 | $1,981,000 | +28.0% | 115,326 | +6.1% | 0.00% | 0.0% |
| Q2 2016 | $1,548,000 | -10.6% | 108,722 | -13.6% | 0.00% | 0.0% |
| Q1 2016 | $1,731,000 | -6.5% | 125,907 | +14.6% | 0.00% | 0.0% |
| Q4 2015 | $1,851,000 | +70.6% | 109,880 | +11.0% | 0.00% | – |
| Q3 2015 | $1,085,000 | -25.9% | 98,951 | -15.5% | 0.00% | -100.0% |
| Q2 2015 | $1,465,000 | -11.3% | 117,099 | -22.1% | 0.00% | – |
| Q1 2015 | $1,652,000 | +26.4% | 150,246 | +78.2% | 0.00% | -100.0% |
| Q4 2014 | $1,307,000 | +161.4% | 84,309 | +103.7% | 0.00% | – |
| Q3 2014 | $500,000 | +190.7% | 41,394 | +209.7% | 0.00% | – |
| Q2 2014 | $172,000 | -8.5% | 13,367 | -13.7% | 0.00% | – |
| Q1 2014 | $188,000 | +526.7% | 15,491 | +486.8% | 0.00% | – |
| Q4 2013 | $30,000 | +36.4% | 2,640 | +23.4% | 0.00% | – |
| Q3 2013 | $22,000 | -92.1% | 2,140 | -91.2% | 0.00% | – |
| Q2 2013 | $280,000 | – | 24,240 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |